<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Matrix metalloproteinases (MMPs) are zinc-endopeptidases with multifactorial actions in central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) <z:mp ids='MP_0001532'>physiology</z:mp> and pathology </plain></SENT>
<SENT sid="1" pm="."><plain>Accumulating data suggest that MMPs have a deleterious role in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>By degrading neurovascular matrix, MMPs promote injury of the blood-brain barrier, <z:hpo ids='HP_0000969'>edema</z:hpo> and <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>By disrupting cell-matrix signaling and homeostasis, MMPs trigger brain cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Hence, there is a movement toward the development of MMP inhibitors for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy </plain></SENT>
<SENT sid="5" pm="."><plain>But MMPs may have a different role during delayed phases after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Because MMPs modulate brain matrix, they may mediate beneficial plasticity and remodeling during <z:hpo ids='HP_0001297'>stroke</z:hpo> recovery </plain></SENT>
<SENT sid="7" pm="."><plain>Here, we show that MMPs participate in delayed cortical responses after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="8" pm="."><plain>MMP-9 is upregulated in peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> cortex at 7-14 days after <z:hpo ids='HP_0001297'>stroke</z:hpo> and is colocalized with markers of neurovascular remodeling </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with MMP inhibitors at 7 days after <z:hpo ids='HP_0001297'>stroke</z:hpo> suppresses neurovascular remodeling, increases ischemic brain injury and impairs functional recovery at 14 days </plain></SENT>
<SENT sid="10" pm="."><plain>MMP processing of bioavailable VEGF may be involved because inhibition of MMPs reduces endogenous VEGF signals, whereas additional treatment with exogenous VEGF prevents MMP inhibitor-induced worsening of infarction </plain></SENT>
<SENT sid="11" pm="."><plain>These data suggest that, contrary to MMP inhibitor therapies for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo>, strategies that modulate MMPs may be needed for promoting <z:hpo ids='HP_0001297'>stroke</z:hpo> recovery </plain></SENT>
</text></document>